This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Korea Research Institute of Bioscience and Biotechnology. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations in Cancer Research: The Contributions of Chan-Woong Park
Introduction: Chan-Woong Park, an innovative inventor based in Bucheon-si, South Korea, is recognized for his significant contributions to cancer research. With a focus on developing methods to inhibit cancer metastasis, Park has made strides in the field of biotechnology. His groundbreaking patent has the potential to pave the way for new therapies that could significantly improve cancer treatment options.
Latest Patents: Chan-Woong Park holds one notable patent titled "Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein." This invention involves the creation of a recombinant expression vector including genes for the extracellular soluble domain of DLK1 and the Fc domain of an IgG antibody. The DLK1-Fc fusion protein, produced and purified from 293E cells, has demonstrated efficacy in inhibiting cancer metastasis. Remarkably, this fusion protein has shown heightened stability compared to non-fusion proteins and has significantly reduced the migration of various cancer cell lines, indicating its promise as an effective ingredient in cancer treatment compositions.
Career Highlights: Chan-Woong Park is affiliated with the Korea Research Institute of Bioscience and Biotechnology, where he conducts advanced research focused on cancer mechanisms and treatments. His work has contributed to the understanding of cancer biology, particularly relating to how certain proteins can influence cancer progression and metastasis.
Collaborations: In his journey, Chan-Woong Park has collaborated with esteemed colleagues, including Young Woo Park and Kiwon Jo. Their joint efforts in research and development have combined their expertise, enriching the discoveries and advancements within the institute in the realm of cancer research and therapy.
Conclusion: Chan-Woong Park's innovative approach to cancer treatment through his patented DLK1-Fc fusion protein reflects his commitment to advancing medical science. His contributions at the Korea Research Institute of Bioscience and Biotechnology are poised to offer significant benefits in cancer therapy, ultimately improving patient outcomes and enhancing the arsenal of tools available to combat cancer metastasis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile